

David J Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1994760/publications.pdf>

Version: 2024-02-01

220
papers

38,272
citations

11651

70
h-index

2953

189
g-index

220
all docs

220
docs citations

220
times ranked

22263
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical End Points in Coronary Stent Trials. <i>Circulation</i> , 2007, 115, 2344-2351.	1.6	4,993
2	Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. <i>New England Journal of Medicine</i> , 2016, 374, 1609-1620.	27.0	3,992
3	Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. <i>New England Journal of Medicine</i> , 2019, 380, 1695-1705.	27.0	3,312
4	TIMER2.0 for analysis of tumor-infiltrating immune cells. <i>Nucleic Acids Research</i> , 2020, 48, W509-W514.	14.5	2,546
5	Transcatheter Mitral-Valve Repair in Patients with Heart Failure. <i>New England Journal of Medicine</i> , 2018, 379, 2307-2318.	27.0	2,079
6	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, S45-S60.	1.4	1,605
7	Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1438-1454.	2.8	1,560
8	Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. <i>Lancet</i> , The, 2016, 387, 2218-2225.	13.7	899
9	Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1735.	7.4	759
10	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019, 381, 2032-2042.	27.0	683
11	Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , 2017, 377, 2240-2252.	27.0	557
12	Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease. <i>Circulation</i> , 2015, 131, 495-502.	1.6	554
13	Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020, 382, 799-809.	27.0	520
14	STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2492-2516.	2.8	511
15	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2224-2234.	2.8	445
16	Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2717-2746.	2.8	416
17	Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2017, 69, 367-377.	2.8	405
18	Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus. <i>Circulation</i> , 2000, 102, E73-86.	1.6	390

#	ARTICLE	IF	CITATIONS
19	Cell-Free DNA and Active Rejection in Kidney Allografts. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2221-2232.	6.1	365
20	Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. <i>Kidney International</i> , 2015, 87, 1061-1073.	5.2	342
21	Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. <i>European Heart Journal</i> , 2021, 42, 1825-1857.	2.2	342
22	Standards for Statistical Models Used for Public Reporting of Health Outcomes. <i>Circulation</i> , 2006, 113, 456-462.	1.6	325
23	Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1408-1419.	27.0	287
24	Health-Related Quality of Life After Transcatheter Aortic Valve Replacement in Inoperable Patients With Severe Aortic Stenosis. <i>Circulation</i> , 2011, 124, 1964-1972.	1.6	278
25	Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Standard Care Among Inoperable Patients With Severe Aortic Stenosis. <i>Circulation</i> , 2012, 125, 1102-1109.	1.6	266
26	Health-Related Quality of Life After Transcatheter or Surgical Aortic Valve Replacement in High-Risk Patients With Severe Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2012, 60, 548-558.	2.8	256
27	Quality of Life after PCI with Drug-Eluting Stents or Coronary-Artery Bypass Surgery. <i>New England Journal of Medicine</i> , 2011, 364, 1016-1026.	27.0	242
28	Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2211-2221.	2.8	240
29	Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1523-1534.	2.9	234
30	State-Transition Modeling. <i>Medical Decision Making</i> , 2012, 32, 690-700.	2.4	231
31	Supervised Exercise, Stent Revascularization, or Medical Therapy for Claudication Due to Aortoiliac Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 999-1009.	2.8	225
32	Predictors of Poor Outcomes After Transcatheter Aortic Valve Replacement. <i>Circulation</i> , 2014, 129, 2682-2690.	1.6	214
33	Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses. <i>Circulation</i> , 2004, 110, 508-514.	1.6	212
34	Vascular Hospitalization Rates and Costs in Patients With Peripheral Artery Disease in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 642-651.	2.2	207
35	Relation of Frailty to Outcomes After Transcatheter Aortic Valve Replacement (from the PARTNER) Tj ETQq1 1 0.784314 rgBT /Overlook	1.6	206
36	Incidence, Predictors, and Prognostic Impact of Late Bleeding Complications After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2605-2615.	2.8	199

#	ARTICLE	IF	CITATIONS
37	The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 459-469.	2.9	179
38	Factors leading to the discard of deceased donor kidneys in the United States. <i>Kidney International</i> , 2018, 94, 187-198.	5.2	178
39	Bioprosthetic Valve Fracture Improves the Hemodynamic Results of Valve-in-Valve Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	173
40	Bleeding Complications After Surgical Aortic Valve Replacement Compared With Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1100-1109.	2.8	167
41	Imaging- and physiology-guided percutaneous coronary intervention without contrast administration in advanced renal failure: a feasibility, safety, and outcome study. <i>European Heart Journal</i> , 2016, 37, 3090-3095.	2.2	158
42	In-Hospital and One-Year Economic Outcomes After Coronary Stenting or Balloon Angioplasty. <i>Circulation</i> , 1995, 92, 2480-2487.	1.6	143
43	Quality of Life After PCI vs CABG Among Patients With Diabetes and Multivessel Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 1581.	7.4	139
44	Use of the Kansas City Cardiomyopathy Questionnaire for Monitoring Health Status in Patients With Aortic Stenosis. <i>Circulation: Heart Failure</i> , 2013, 6, 61-67.	3.9	137
45	Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. <i>Circulation</i> , 2021, 143, 479-500.	1.6	132
46	Prediction of Poor Outcome After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1868-1877.	2.8	128
47	Ticagrelor With or Without Aspirin After Complex APCI. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2414-2424.	2.8	122
48	Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk. <i>Circulation</i> , 2019, 139, 877-888.	1.6	120
49	3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1029-1040.	2.8	113
50	Quality-of-Life Outcomes After Transcatheter Aortic Valve Replacement in an Unselected Population. <i>JAMA Cardiology</i> , 2017, 2, 409.	6.1	110
51	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , 2016, 182, 125-134.	2.7	108
52	Cost-Effectiveness of Percutaneous Coronary Intervention With Drug Eluting Stents Versus Bypass Surgery for Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease. <i>Circulation</i> , 2013, 127, 820-831.	1.6	107
53	Health Status Benefits of Transcatheter vs Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk. <i>JAMA Cardiology</i> , 2017, 2, 837.	6.1	105
54	Health Status After Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Increased Surgical Risk. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1207-1217.	2.9	100

#	ARTICLE	IF	CITATIONS
55	How to Define a Poor Outcome After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 591-597.	2.2	96
56	Rethinking Composite End Points in Clinical Trials. <i>Circulation</i> , 2014, 130, 1254-1261.	1.6	96
57	Health Status After Transcatheter Mitral-Valve Repair in Heart Failure and Secondary Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2123-2132.	2.8	94
58	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.	2.2	93
59	STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. <i>Annals of Thoracic Surgery</i> , 2021, 111, 701-722.	1.3	91
60	Impact of Smoking on Clinical and Angiographic Restenosis After Percutaneous Coronary Intervention. <i>Circulation</i> , 2001, 104, 773-778.	1.6	87
61	Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1880-1889.	2.9	87
62	Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the MANTA Percutaneous Vascular Closure Device. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007258.	3.9	87
63	Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1746-1756.	2.9	84
64	Cost-Effectiveness of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Bypass Surgery for Patients With 3-Vessel or Left Main Coronary Artery Disease. <i>Circulation</i> , 2014, 130, 1146-1157.	1.6	83
65	The weekend effect alters the procurement and discard rates of deceased donor kidneys in the United States. <i>Kidney International</i> , 2016, 90, 157-163.	5.2	83
66	Early Outcomes of Outpatient Management of Kidney Transplant Recipients with Coronavirus Disease 2019. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1174-1178.	4.5	81
67	Peripheral Artery Disease and Transcatheter Aortic Valve Replacement Outcomes. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	79
68	Association Between Declined Offers of Deceased Donor Kidney Allograft and Outcomes in Kidney Transplant Candidates. <i>JAMA Network Open</i> , 2019, 2, e1910312.	5.9	78
69	Impact of Smoking on Health-Related Quality of Life After Percutaneous Coronary Revascularization. <i>Circulation</i> , 2000, 102, 1369-1374.	1.6	76
70	Costs of Periprocedural Complications in Patients Treated With Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 829-836.	3.9	76
71	Health Status After Transcatheter Aortic Valve Replacement in Patients at Extreme Surgical Risk. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 315-323.	2.9	76
72	Fractional Flow Reserve Compared With Intravascular Ultrasound Guidance for Optimizing Stent Deployment. <i>Circulation</i> , 2001, 104, 1917-1922.	1.6	73

#	ARTICLE	IF	CITATIONS
73	Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 1277-1287.	2.9	73
74	Five-Year Outcomes of Endoscopic Sleeve Gastroplasty for the Treatment of Obesity. Clinical Gastroenterology and Hepatology, 2021, 19, 1051-1057.e2.	4.4	72
75	Quality-of-Life After Everolimus-Eluting Stents or Bypass Surgery for Left-Main Disease. Journal of the American College of Cardiology, 2017, 70, 3113-3122.	2.8	69
76	Effect of Medication Co-payment Vouchers on P2Y ₁₂ Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction. JAMA - Journal of the American Medical Association, 2019, 321, 44.	7.4	67
77	Transapical and Transaortic Transcatheter Aortic Valve Replacement in the United States. Annals of Thoracic Surgery, 2015, 100, 1718-1727.	1.3	66
78	Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal Disease. Journal of the American Heart Association, 2016, 5, .	3.7	65
79	Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement: Results From the Transcatheter Valve Therapy Registry. Circulation, 2021, 143, 2229-2240.	1.6	64
80	Admission to Hospitals With On-Site Cardiac Catheterization Facilities. Circulation, 1998, 98, 2010-2016.	1.6	63
81	Quality of Life After Surgery or DES in Patients With 3-Vessel or Left Main Disease. Journal of the American College of Cardiology, 2017, 69, 2039-2050.	2.8	63
82	Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. American Heart Journal, 2017, 183, 62-68.	2.7	60
83	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2020, 75, 2403-2413.	2.8	60
84	Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications. Journal of Applied Laboratory Medicine, 2017, 2, 309-321.	1.3	59
85	Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome. Kidney International Reports, 2019, 4, 434-446.	0.8	59
86	Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2020, 8, 8-23.e18.	1.6	55
87	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1349-1357.	2.9	54
88	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. European Heart Journal, 2021, 42, 4624-4634.	2.2	54
89	The global aHUS registry: methodology and initial patient characteristics. BMC Nephrology, 2015, 16, 207.	1.8	52
90	Performance and Validation of the U.S. NCDRA Acute Kidney Injury Prediction Model in Japan. Journal of the American College of Cardiology, 2016, 67, 1715-1722.	2.8	51

#	ARTICLE	IF	CITATIONS
91	Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation. <i>Circulation</i> , 2019, 140, 1881-1891.	1.6	51
92	Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons Versus Standard Percutaneous Transluminal Angioplasty. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2343-2352.	2.9	50
93	Relationship of Albuminuria and Renal Artery Stent Outcomes. <i>Hypertension</i> , 2016, 68, 1145-1152.	2.7	50
94	Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 138-147.	2.9	49
95	Inclusion of Functional Status Measures in the Risk Adjustment of 30-Day Mortality After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 581-589.	2.9	49
96	Development and Application of a Risk Prediction Model for In-Hospital Stroke After Transcatheter Aortic Valve Replacement: A Report From The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1097-1103.	1.3	49
97	The Effect and Relationship of Frailty Indices on Survival After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 219-231.	2.9	49
98	The impact of dyspnea on health-related quality of life in patients with coronary artery disease: Results from the PREMIER registry. <i>American Heart Journal</i> , 2009, 157, 1042-1049.e1.	2.7	48
99	Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: One-year results from the SYNTAX trial. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 198-209.	1.7	48
100	Association of Patient-Reported Health Status With Long-Term Mortality After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002875.	3.9	47
101	Prognostic Implications of Creatine Kinase-MB Elevation After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 474-480.	3.9	45
102	The Outcomes, Patient Health Status, and Efficiency IN Chronic Total Occlusion Hybrid Procedures registry. <i>Coronary Artery Disease</i> , 2017, 28, 110-119.	0.7	45
103	Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1954-1962.	2.9	44
104	Variation in Hospital Risk-Adjusted Mortality Rates Following Transcatheter Aortic Valve Replacement in the United States. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 560-565.	2.2	43
105	Postvaccine Anti-SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2021, 6, 1699-1700.	0.8	37
106	Racial, Ethnic, and Socioeconomic Disparities in Access to Transcatheter Aortic Valve Replacement Within Major Metropolitan Areas. <i>JAMA Cardiology</i> , 2022, 7, 150.	6.1	37
107	Association of Transcatheter Mitral Valve Repair With Quality of Life Outcomes at 30 Days and 1 Year. <i>JAMA Cardiology</i> , 2018, 3, 1151.	6.1	36
108	Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts. <i>Kidney International</i> , 2018, 94, 1189-1198.	5.2	36

#	ARTICLE	IF	CITATIONS
109	Predicting Quality of Life at 1 Year After Transcatheter Aortic Valve Replacement in a Real-World Population. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004693.	2.2	35
110	Balancing the risks of bleeding and stent thrombosis: A decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. <i>American Heart Journal</i> , 2015, 169, 222-233.e5.	2.7	34
111	Predictors of Clinical Response to Transcatheter Reduction of Secondary Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1007-1014.	2.8	34
112	Immediate post-procedural functional assessment of percutaneous coronary intervention: current evidence and future directions. <i>European Heart Journal</i> , 2021, 42, 2695-2707.	2.2	34
113	Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2021, 78, 314-317.	1.9	34
114	NYHA Functional Classification and Outcomes After Transcatheter Mitral Valve Repair in Heart Failure. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2317-2328.	2.9	33
115	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	32
116	Impact of a Claims-Based Frailty Indicator on the Prediction of Long-Term Mortality After Transcatheter Aortic Valve Replacement in Medicare Beneficiaries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e005048.	2.2	32
117	Prediction of residual angina after percutaneous coronary intervention. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2015, 1, 23-30.	4.0	30
118	Durability of quality of life benefits of transcatheter aortic valve replacement: Long-term results from the CoreValve US extreme risk trial. <i>American Heart Journal</i> , 2017, 194, 39-48.	2.7	30
119	Impact of short-term complications of transcatheter aortic valve replacement on longer-term outcomes: results from the STS/ACC Transcatheter Valve Therapy Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 208-213.	4.0	29
120	In-Hospital Costs and Costs of Complications of Chronic Total Occlusion Angioplasty. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 323-331.	2.9	28
121	Cost-Effectiveness of Supervised Exercise, Stenting, and Optimal Medical Care for Claudication: Results From the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e001233.	3.7	27
122	Socioeconomic and Geographic Characteristics of Hospitals Establishing Transcatheter Aortic Valve Replacement Programs, 2012-2018. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008260.	2.2	27
123	Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. <i>American Heart Journal</i> , 2015, 170, 1140-1150.	2.7	26
124	Hospital Resource Utilization Before and After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1135-1146.	2.8	26
125	Association of Physician Variation in Use of Manual Aspiration Thrombectomy With Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. <i>JAMA Cardiology</i> , 2019, 4, 110.	6.1	26
126	Composite Metric for Benchmarking Site Performance in Transcatheter Aortic Valve Replacement: Results From the STS/ACC TVT Registry. <i>Circulation</i> , 2021, 144, 186-194.	1.6	26

#	ARTICLE	IF	CITATIONS
127	Temporal Trends in Quality of Life Outcomes After Transapical Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 338-346.	2.2	25
128	Effect of SAPIEN 3 Transcatheter Valve Implantation on Health Status in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1188-1198.	2.9	25
129	The Norwood operation: Relative effects of surgeon and institutional volumes on outcomes and resource utilization. <i>Cardiology in the Young</i> , 2016, 26, 683-692.	0.8	24
130	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006144.	3.9	24
131	Health Status Changes and Outcomes in Patients With Heart Failure and Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2099-2106.	2.8	24
132	Kidney allograft biopsy findings after COVID-19. <i>American Journal of Transplantation</i> , 2021, 21, 4032-4042.	4.7	24
133	Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 527-538.	2.8	23
134	Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable?. <i>American Heart Journal</i> , 2014, 168, 103-109.	2.7	22
135	Outcomes of kidney transplant from deceased donors with acute kidney injury and prolonged cold ischemia time - a retrospective cohort study. <i>Transplant International</i> , 2019, 32, 646-657.	1.6	22
136	Dyspnea Among Patients With Chronic Total Occlusions Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	21
137	Impact of Deceased Donor Kidney Procurement Biopsy Technique on Histologic Accuracy. <i>Kidney International Reports</i> , 2020, 5, 1906-1913.	0.8	21
138	Association of HLA Typing and Alloimmunity With Posttransplantation Membranous Nephropathy: A Multicenter Case Series. <i>American Journal of Kidney Diseases</i> , 2020, 76, 374-383.	1.9	21
139	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008226.	3.9	21
140	Perspectives on COVID-19 vaccination among kidney and pancreas transplant recipients living in New York City. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 2040-2045.	1.0	21
141	Surgical Versus Percutaneous Femoral Access for Delivery of Large-Bore Cardiovascular Devices (from the PARTNER Trial). <i>American Journal of Cardiology</i> , 2016, 117, 1643-1650.	1.6	19
142	Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 651-658.	2.9	19
143	Outcomes of retrograde chronic total occlusion percutaneous coronary intervention: A report from the OPEN-CTO registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1162-1173.	1.7	19
144	Clinical and economic outcomes among elderly myocardial infarction survivors in the United States. <i>Cardiovascular Therapeutics</i> , 2016, 34, 450-459.	2.5	18

#	ARTICLE	IF	CITATIONS
145	Periprocedural Stroke and Myocardial Infarction as Risks for Long-Term Mortality in CREST. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004663.	2.2	18
146	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. European Heart Journal, 2021, 42, 4683-4693.	2.2	18
147	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007133.	3.9	17
148	Defining a Clinically Important Change in 6-Minute Walk Distance in Patients With Heart Failure and Mitral Valve Disease. Circulation: Heart Failure, 2021, 14, e007564.	3.9	17
149	Transcatheter Aortic Valve Replacement in Low-Population Density Areas. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006245.	2.2	17
150	Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. Circulation: Cardiovascular Interventions, 2015, 8, e001712.	3.9	16
151	Baseline Functional Capacity and Transcatheter Mitral Valve Repair in Heart Failure With Secondary Mitral Regurgitation. JACC: Cardiovascular Interventions, 2020, 13, 2331-2341.	2.9	16
152	Deceased Donor Kidneys Are Harder to Place on the Weekend. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 904-906.	4.5	15
153	Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. Journal of the American Heart Association, 2016, 5, .	3.7	14
154	Association of measured platelet reactivity with changes in P2Y ₁₂ receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the Treatment with ADP receptor inhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. American Heart Journal, 2017, 187, 19-28.	2.7	14
155	Practical Application of Patient-Reported Health Status Measures for Transcatheter Valve Therapies. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007187.	2.2	14
156	Role of Frailty in Identifying Benefit From Transcatheter Versus Surgical Aortic Valve Replacement. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, .	2.2	14
157	Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation. Heart, 2022, , heartjnl-2021-320005.	2.9	14
158	Practical Approaches to Mitigating Economic Barriers to Living Kidney Donation for Patients and Programs. Current Transplantation Reports, 2017, 4, 24-31.	2.0	12
159	Association between the "Timed Up and Go Test" at transplant evaluation and outcomes after kidney transplantation. Clinical Transplantation, 2018, 32, e13410.	1.6	12
160	Regional Disparities in Transplantation With Deceased Donor Kidneys With Kidney Donor Profile Index Less Than 20% Among Candidates With Top 20% Estimated Post Transplant Survival. Progress in Transplantation, 2019, 29, 354-360.	0.7	12
161	Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective. Value in Health Regional Issues, 2017, 12, 74-83.	1.2	11
162	Analysis of Adverse Events Related to Impella Usage (from the Manufacturer and User Facility Device) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	11

#	ARTICLE	IF	CITATIONS
163	Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 1115-1123.	2.1	11
164	Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA. <i>Circulation</i> , 2022, 145, 1294-1307.	1.6	11
165	Early Post-Discharge Bleeding and Antiplatelet Therapy Discontinuation Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1700-1702.	2.8	10
166	Economic Implications of Transcatheter Aortic Valve Replacement in Patients at Intermediate Surgical Risk. <i>Circulation</i> , 2016, 134, 1416-1418.	1.6	10
167	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Tj ETQq1 1 0.784314 rgBT /Over	1.6	10
168	Outcomes for potential kidney transplant recipients offered public health service increased risk kidneys: A single-center experience. <i>Clinical Transplantation</i> , 2018, 32, e13427.	1.6	10
169	COVID-19 in pancreas transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 22, e13359.	1.7	10
170	Neutrophil-to-Lymphocyte Ratios in Patients Undergoing Aortic Valve Replacement: The PARTNER Trials and Registries. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	10
171	Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes. <i>Clinical Kidney Journal</i> , 2021, 14, 2075-2084.	2.9	9
172	Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010258.	3.9	9
173	Declined Offers for Deceased Donor Kidneys Are Not an Independent Reflection of Organ Quality. <i>Kidney360</i> , 2021, 2, 1807-1818.	2.1	9
174	Clinical Predictors and Prognosis of Recurrent IgA Nephropathy in the Kidney Allograft. <i>Glomerular Diseases</i> , 2022, 2, 42-53.	1.0	9
175	Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	8
176	Association of Stress Test Risk Classification With Health Status After Chronic Total Occlusion Angioplasty (from the Outcomes, Patient Health Status and Efficiency in Chronic Total Occlusion) Tj ETQq0 0 0 rgBT /Overlook 10 Tf 50	1.4	10
177	Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill. <i>JAMA Cardiology</i> , 2020, 5, 532.	6.1	8
178	Treatment of borderline infiltrates with minimal inflammation in kidney transplant recipients has no effect on allograft or patient outcomes. <i>Clinical Transplantation</i> , 2020, 34, e14019.	1.6	8
179	Prognostic Importance of Health Status Versus Functional Status in Heart Failure and Secondary Mitral Regurgitation. <i>JACC: Heart Failure</i> , 2021, 9, 684-692.	4.1	8
180	A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation*. <i>Critical Care Medicine</i> , 2022, 50, 1348-1359.	0.9	8

#	ARTICLE	IF	CITATIONS
181	Transplant tourism: a growing phenomenon. <i>Nature Reviews Nephrology</i> , 2009, 5, 128-129.	9.6	7
182	Health Status Outcomes in Patients With Acute Myocardial Infarction After Rehospitalization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 777-784.	2.2	7
183	Predicting Likelihood for Coronary Artery Bypass Grafting After Non-ST-Elevation Myocardial Infarction: Finding the Best Prediction Model. <i>Annals of Thoracic Surgery</i> , 2016, 102, 1304-1311.	1.3	7
184	Variation in Antithrombotic Therapy and Clinical Outcomes in Patients With Preexisting Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009963.	3.9	7
185	Identification of Frailty Using a Claims-Based Frailty Index in the CoreValve Studies: Findings from the EXTEND-FRAILTY Study. <i>Journal of the American Heart Association</i> , 2021, 10, e022150.	3.7	7
186	Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 774-782.	2.9	6
187	Change in Hospitalization Rates Following Transcatheter Mitral Valve Repair. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008342.	3.9	6
188	Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications. <i>JAMA Cardiology</i> , 2020, 5, 38.	6.1	6
189	Orthopedic Principles to Facilitate Enhanced Recovery After Cardiac Surgery. <i>Critical Care Clinics</i> , 2020, 36, 617-630.	2.6	6
190	Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006511.	2.2	6
191	Febrile neutropenia after kidney transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 3436-3443.	4.7	6
192	Utilization, Costs, and Outcomes of Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010310.	3.9	6
193	Eculizumab (ECU) in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Progressing Thrombotic Microangiopathy (TMA): 2-Year Data.. <i>Blood</i> , 2012, 120, 2084-2084.	1.4	6
194	Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006182.	2.2	5
195	# SoMe for # IC : Optimal use of social media in interventional cardiology. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 97-106.	1.7	5
196	Why Is Intravascular Ultrasound Guidance Underutilized in Percutaneous Coronary Intervention?: It Is Not All About the Benjamins. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007844.	2.2	5
197	Patient-reported vs. physician-estimated symptoms before and after transcatheter aortic valve replacement. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 161-168.	4.0	5
198	Predicting Residual Angina After Chronic Total Occlusion Percutaneous Coronary Intervention: Insights from the OPEN-CTO Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e024056.	3.7	5

#	ARTICLE	IF	CITATIONS
199	Racial Heterogeneity in Treatment Effects in Peripheral Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004157.	2.2	4
200	Unmeasured, unknown, and hidden: Confounders are not always in plain sight. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, e237-e238.	0.8	4
201	Two-year PAD-related health care costs in patients undergoing lower extremity endovascular revascularization: results from the LIBERTY 360Â° trial. <i>Journal of Medical Economics</i> , 2021, 24, 570-580.	2.1	4
202	Comparative Effectiveness Research and Cardiovascular Device Registries: Aligning Policy and Methods. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007911.	2.2	4
203	Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Resistant to Plasma Exchange/Infusion (PE/PI): Results of An Extension Study. <i>Blood</i> , 2011, 118, 193-193.	1.4	4
204	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS120009495.	3.9	4
205	Grand Challenges in Pediatric Otolaryngology. <i>Frontiers in Pediatrics</i> , 2013, 1, 10.	1.9	3
206	The clinical significance of receiving a kidney allograft from deceased donor with chronic histologic changes. <i>Modern Pathology</i> , 2021, 34, 1795-1805.	5.5	3
207	Anxiety and Depression Following Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2022, 11, e024377.	3.7	3
208	Transradial Percutaneous Coronary Intervention... Works Great! Less Billing!. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004667.	2.2	2
209	Patient Characteristics Associated With Antianginal Medication Escalation and De-Escalation Following Chronic Total Occlusion Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005287.	2.2	2
210	Transcatheter Aortic Valve Replacement After Prior Mitral Valve Surgery: Results From the Transcatheter Valve Therapy Registry. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1789-1796.	1.3	2
211	Insulin Sensitivity After Living Donor Nephrectomy. <i>Transplantation Proceedings</i> , 2021, 53, 1858-1864.	0.6	2
212	Effect of intensive versus limited monitoring on clinical trial conduct and outcomes: A randomized trial. <i>American Heart Journal</i> , 2022, 243, 77-86.	2.7	2
213	Transporting Results of TAVR Trials to the Real World. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2124-2126.	2.9	1
214	Impact of Transcatheter Aortic Valve Replacement on Hospitalization Rates: Insights From Nationwide Readmission Database. <i>Journal of the American Heart Association</i> , 2021, 10, e022910.	3.7	1
215	The Challenges of Success. <i>Circulation</i> , 2014, 130, 1343-1345.	1.6	0
216	Weighing the potential late benefits versus early hazard associated with bioresorbable vascular scaffolds in percutaneous coronary interventions: a Markov decision analytic model. <i>Coronary Artery Disease</i> , 2020, 31, 230-236.	0.7	0

#	ARTICLE	IF	CITATIONS
217	Healthcare students support opt-out organ donation for practical and moral reasons. Journal of Medical Ethics, 2022, 48, 522-529.	1.8	0
218	Baseline Demographics and Characteristics of 466 Patients with Atypical Hemolytic Uremic Syndrome in the Global aHUS Registry. Blood, 2014, 124, 4204-4204.	1.4	0
219	The Global aHUS Registry: Characteristics of 826 Patients with Atypical Hemolytic Uremic Syndrome. Blood, 2015, 126, 4640-4640.	1.4	0
220	Response to: Correspondence on 'Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation does need confirmation' by Armoiry and Connock. Heart, 2022, , heartjnl-2022-321180.	2.9	0